Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

Current Medical Research and Opinion

Volumn 20, Issue 9, 2004, Pages 1385-1392

  Athyros, Vasilios G ^a,e   Mikhailidis, Dimitri P ^b   Papageorgiou, Athanasios A ^a   Symeonidis, Athanasios N ^c   Daskalopoulou, Stella S ^b   Kakafika, Anna I ^a   Pehlivanidis, Anthimos N ^a   Bouloukos, Vasilios I ^a   Langer, Anatoly ^d  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c Greek Soc of General Practitioners   (Greece)

^d Division of Cardiology   (Canada)

^e NONE   (Greece)

Author keywords

Atorvastatin; Coronary events; Coronary heart disease; Low density lipoprotein cholesterol (LDL C)

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DEATH; DIABETES MELLITUS; DOSE RESPONSE; DYSLIPIDEMIA; FOLLOW UP; GREECE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 5444260200     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125004484     Document Type: Article

References (32)

1. Scandinavian Simvastatin Survival Study (4S) Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994;344:1383-9
2. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998;97:1453-60
3. Sacks FM, Pfeffer MA, Moye LA, et al., for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 1996;335:1001-9
4. Long-term Intervention with Pravastatin Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med 1998;339:1349-57
5. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22
6. Howard BV, Robbins DC, Sievers JL, et al. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL. The Strong Heart Study. Arterioscler Thromb Vasc Biol 2000;20:830-5
7. Schwartz GG, Olsson AG, Ezekowitz MD, et al. [Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators]. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. J Am Med Assoc 2001;285:1711-8
8. Cannon CP, Braunwald E, McCabe CH, et al. [Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators]. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. New Engl J Med 2004;350:495-504
9. Nissen SE, Tuscu EM, Shoenhagen P, et al. Effect of intensive compared with moderate lipid lowering therapy on the progression of atherosclerosis. J Am Med Assoc 2004;291:1071-80
10. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-5811.
11. Athyros, VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goals versus usual care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 2002;18:220-8
12. Adult Treatment Panel III. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. J Am Med Assoc 2001;285:2486-97
13. Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. New Engl J Med 1997;336:153-62
14. Knatterud GL, Rosenberg Y, Campeau L, et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. [Post CABG Investigators]. Circulation 2000;102:157-65
15. [West of Scotland Coronary Prevention Study Group], Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 1995;333:1301-7
16. Sacks FM, Moye LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998;97:1446-52
17. Pfeffer MA, Sacks FM, Moye LA, et al. Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events. J Am Coll Cardiol 1999;33:125-30
18. Simes RJ, Marschner IC, Hunt D, et al., for the LIPID Study Investigators. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 2002;105:1162-9
19. Forrester JS, Bairey-Merz CN, Kaul S. The aggressive low density lipoprotein lowering controversy. J Am Coll Cardiol 2000;36:1419-25
20. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). J Am Med Assoc 1986;256:2823-8
21. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc 2002;288:2981-97
22. Athyros VG, Papageorgiou AA, Symeonidis AN, Elisaf M. Non-high density lipoprotein cholesterol and coronary events during long-term statin treatment. Atherosclerosis 2003;168:397-8
23. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al., for the GREACE Study Collaborative Group. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events. A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 2004;20:627-37
24. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. J Clin Pathol 2004;57:728-34
25. Athyros VG, Papageorgiou AA, Elisaf M, Mikhailidis DP for the GREACE Study Collaborative Group. Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin 2003;19:615-7
26. Athyros VG, Elisaf M, Papageorgiou AA, et al. for the GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004;43:589-99
27. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens 2004 [in press]
28. Athyros VG, Papageorgiou AA, Symeonidis AN, et al., for the GREACE Study Collaborative Group. Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. Angiology 2003;54:679-90
29. Kontopoulos AG, Athyros VG, Pehlivanidis AN, Demitriadis DS, Papageorgiou AA, Boudoulas H. Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients. Curr Med Res Opin 2003;19:22-7
30. Pehlivanidis AN, Athyros VG, Demitriadis DS, Papageorgiou AA, Bouloukos VJ, Kontopoulos AG. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis 2001;157:463-9
31. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003;19:540-56
32. EASE Trial: Ezetimibe Add-on to Statin for Effectiveness Trial. Presented at the American College of Cardiology Annual Scientific Sessions 2004; New Orleans, Louisiana: March 7-10. Available at: http://www.cardiosource.com/ webfiles/editorial/ cardio/meetings/acc04_rapidweds.htm